The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells
In the clinical practice, the combination of 5-fluorouracil (5-FU) + Adriamycin (also known as doxorubicin, DOX) + cyclophosphamide (CYA) (known as FAC) is used to treat breast cancer. The FAC therapy, however, carries some serious risks, namely potential cardiotoxic effects, although the mechanisms...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | http://www.mdpi.com/2218-273X/9/3/98 |
id |
doaj-5651537f0b00485f8fc0cefd822ded64 |
---|---|
record_format |
Article |
spelling |
doaj-5651537f0b00485f8fc0cefd822ded642020-11-25T00:32:56ZengMDPI AGBiomolecules2218-273X2019-03-01939810.3390/biom9030098biom9030098The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated CellsAna Reis-Mendes0Félix Carvalho1Fernando Remião2Emília Sousa3Maria de Lourdes Bastos4Vera Marisa Costa5UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, PortugalUCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, PortugalUCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, PortugalLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, PortugalUCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, PortugalUCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, PortugalIn the clinical practice, the combination of 5-fluorouracil (5-FU) + Adriamycin (also known as doxorubicin, DOX) + cyclophosphamide (CYA) (known as FAC) is used to treat breast cancer. The FAC therapy, however, carries some serious risks, namely potential cardiotoxic effects, although the mechanisms are still unclear. In the present study, the role of the main metabolites regarding FAC-induced cardiotoxicity was assessed at clinical relevant concentrations. Seven-day differentiated H9c2 cells were exposed for 48 h to the main metabolites of FAC, namely the metabolite of 5-FU, α-fluoro-β-alanine (FBAL, 50 or 100 μM), of DOX, doxorubicinol (DOXOL, 0.2 or 1 μM), and of CYA, acrolein (ACRO, 1 or 10 μM), as well as to their combination. The parent drugs (5-FU 50 μM, DOX 1 μM, and CYA 50 μM) were also tested isolated or in combination with the metabolites. Putative cytotoxicity was evaluated through phase contrast microscopy, Hoechst staining, membrane mitochondrial potential, and by two cytotoxicity assays: the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and the neutral red (NR) lysosomal incorporation. The metabolite DOXOL was more toxic than FBAL and ACRO in the MTT and NR assays. When in combination, neither FBAL nor ACRO increased DOXOL-induced cytotoxicity. No nuclear condensation was observed for any of the tested combinations; however, a significant mitochondrial potential depolarization after FBAL 100 μM + DOXOL 1 μM + ACRO 10 μM or FBAL 100 μM + DOXOL 1 μM exposure was seen at 48 h. When tested alone DOX 1 μM was more cytotoxic than all the parent drugs and metabolites in both the cytotoxicity assays performed. These results demonstrated that DOXOL was the most toxic of all the metabolites tested; nonetheless, the metabolites do not seem to be the major contributors to FAC-induced cardiotoxicity in this cardiac model.http://www.mdpi.com/2218-273X/9/3/98doxorubicinolfluoro-β-alanineacroleincardiotoxicitydifferentiated H9c2 cells |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ana Reis-Mendes Félix Carvalho Fernando Remião Emília Sousa Maria de Lourdes Bastos Vera Marisa Costa |
spellingShingle |
Ana Reis-Mendes Félix Carvalho Fernando Remião Emília Sousa Maria de Lourdes Bastos Vera Marisa Costa The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells Biomolecules doxorubicinol fluoro-β-alanine acrolein cardiotoxicity differentiated H9c2 cells |
author_facet |
Ana Reis-Mendes Félix Carvalho Fernando Remião Emília Sousa Maria de Lourdes Bastos Vera Marisa Costa |
author_sort |
Ana Reis-Mendes |
title |
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells |
title_short |
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells |
title_full |
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells |
title_fullStr |
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells |
title_full_unstemmed |
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells |
title_sort |
main metabolites of fluorouracil + adriamycin + cyclophosphamide (fac) are not major contributors to fac toxicity in h9c2 cardiac differentiated cells |
publisher |
MDPI AG |
series |
Biomolecules |
issn |
2218-273X |
publishDate |
2019-03-01 |
description |
In the clinical practice, the combination of 5-fluorouracil (5-FU) + Adriamycin (also known as doxorubicin, DOX) + cyclophosphamide (CYA) (known as FAC) is used to treat breast cancer. The FAC therapy, however, carries some serious risks, namely potential cardiotoxic effects, although the mechanisms are still unclear. In the present study, the role of the main metabolites regarding FAC-induced cardiotoxicity was assessed at clinical relevant concentrations. Seven-day differentiated H9c2 cells were exposed for 48 h to the main metabolites of FAC, namely the metabolite of 5-FU, α-fluoro-β-alanine (FBAL, 50 or 100 μM), of DOX, doxorubicinol (DOXOL, 0.2 or 1 μM), and of CYA, acrolein (ACRO, 1 or 10 μM), as well as to their combination. The parent drugs (5-FU 50 μM, DOX 1 μM, and CYA 50 μM) were also tested isolated or in combination with the metabolites. Putative cytotoxicity was evaluated through phase contrast microscopy, Hoechst staining, membrane mitochondrial potential, and by two cytotoxicity assays: the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and the neutral red (NR) lysosomal incorporation. The metabolite DOXOL was more toxic than FBAL and ACRO in the MTT and NR assays. When in combination, neither FBAL nor ACRO increased DOXOL-induced cytotoxicity. No nuclear condensation was observed for any of the tested combinations; however, a significant mitochondrial potential depolarization after FBAL 100 μM + DOXOL 1 μM + ACRO 10 μM or FBAL 100 μM + DOXOL 1 μM exposure was seen at 48 h. When tested alone DOX 1 μM was more cytotoxic than all the parent drugs and metabolites in both the cytotoxicity assays performed. These results demonstrated that DOXOL was the most toxic of all the metabolites tested; nonetheless, the metabolites do not seem to be the major contributors to FAC-induced cardiotoxicity in this cardiac model. |
topic |
doxorubicinol fluoro-β-alanine acrolein cardiotoxicity differentiated H9c2 cells |
url |
http://www.mdpi.com/2218-273X/9/3/98 |
work_keys_str_mv |
AT anareismendes themainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT felixcarvalho themainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT fernandoremiao themainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT emiliasousa themainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT mariadelourdesbastos themainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT veramarisacosta themainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT anareismendes mainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT felixcarvalho mainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT fernandoremiao mainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT emiliasousa mainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT mariadelourdesbastos mainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells AT veramarisacosta mainmetabolitesoffluorouraciladriamycincyclophosphamidefacarenotmajorcontributorstofactoxicityinh9c2cardiacdifferentiatedcells |
_version_ |
1725318218085564416 |